2019 Year 11 Month 28 Today, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security announced the latest list of drugs approved for inclusion in national medical insurance negotiations. Biotech Pharma’s nivolumab is among them. Nimotuzumab ) Successfully passed the national medical insurance negotiation once again and has been included in the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List"!

　　Previously, nivolumab had 2017 This year, it was included in the National Medical Insurance Catalogue through national healthcare negotiations—and now, its successful renewal in these same negotiations will help even more cancer patients, further easing their financial burden.

　　Nimotuzumab is a targeted therapy approved in China for the treatment of nasopharyngeal carcinoma, marketed under the brand name Tai Xin Sheng. Clinically, it is primarily used in combination with radiotherapy or chemoradiotherapy to target epidermal growth factor receptors. (EGFR) Positively expressed III/IV Early-stage nasopharyngeal cancer. 2009 The year has been enshrined in the NCCN "The Clinical Practice Guideline for Head and Neck Tumors (China Edition)" recommends nivolumab as a first-line treatment for locally advanced nasopharyngeal carcinoma. Currently, nivolumab is approved in China, the United States, Germany, Canada, Japan, Cuba, India, and other countries. 20 Several countries are conducting multiple clinical studies, with ongoing or already completed clinical trials totaling approximately 100 The remaining treatments include TaiXinSheng combined with radiotherapy and chemotherapy for the treatment of nasopharyngeal carcinoma, head and neck tumors, gliomas, colorectal cancer, pancreatic cancer, esophageal cancer, liver cancer, non-small cell lung cancer, and other solid tumors. Clinical studies have demonstrated that patients achieve high disease control rates, significant survival benefits, and mild adverse effects, highlighting the treatment's substantial clinical value.